Medical Oncology

, Volume 28, Issue 4, pp 991–998 | Cite as

Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes

  • In Sil Choi
  • Hye Seung Lee
  • Keun-Wook LeeEmail author
  • Haeryoung Kim
  • Ki Hwan Kim
  • Yu Jung Kim
  • Jee Hyun Kim
  • Woo Ho Kim
  • Jong Seok Lee
Original Paper


This study was performed to analyze the impact of protein expression related to fluoropyrimidine and cisplatin metabolism (thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, orotate phosphoribosyltransferase [OPRT], excision repair cross-complementation 1, Fanconi anemia complementation group D2, glutathione S-transferase P1, and X-ray repair cross-complementing group 1) on treatment outcomes in patients with metastatic or relapsed gastric cancer (MRGC) receiving S-1/cisplatin chemotherapy. Protein expression was measured by immunohistochemistry (IHC). Of the 43 patients who had received S-1 (80 mg/m2/day; days 1–14) and cisplatin (60 mg/m2; day 1) every 3 weeks and had available tissue blocks, IHC was successfully performed in 41 patients. Patients with high OPRT levels in tumor tissues (IHC score ≥6) had superior progression-free survival (PFS) (23.3 vs. 14.1 weeks [median]) and overall survival (OS) (72.4 vs. 55.4 weeks [median]) to those with low OPRT levels (IHC score ≤5; P-values <.05). Expression levels of other proteins were not predictive of treatment outcomes. In multivariate analysis, both a good performance status and a high OPRT level were independently associated with prolonged PFS and OS. The OPRT expression level may be a good predictive marker in S-1/cisplatin-treated patients with MRGC.


S-1 Cisplatin Chemotherapy Gastric cancer Orotate phosphoribosyltransferase Biomarker 



This study was partially supported by grants from Korean Cancer Research Foundation, Seoul National University Bundang Hospital Research Fund (11-2008-034), and Seoul Municipal Boramae Hospital Clinical Research Fund.


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRefGoogle Scholar
  2. 2.
    Vanhoefer U, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000;18:2648–57.PubMedGoogle Scholar
  3. 3.
    Cunningham D, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.PubMedCrossRefGoogle Scholar
  4. 4.
    Kang YK, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Choi IS, et al. Oxaliplatin, 5-FU, folinic acid as first-line palliative chemotherapy in elderly patients with metastatic or recurrent gastric cancer. Cancer Res Treat. 2007;39:99–103.PubMedCrossRefGoogle Scholar
  6. 6.
    Koizumi W, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003;89:2207–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Ajani JA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24:663–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Lee JL, et al. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemother Pharmacol. 2008;61:837–45.PubMedCrossRefGoogle Scholar
  9. 9.
    Koizumi W, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Boku N, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res. 1998;4:1469–74.PubMedGoogle Scholar
  11. 11.
    Metzger R, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998;16:309–16.PubMedGoogle Scholar
  12. 12.
    Miyamoto S. et al. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer. Int J Oncol. 2000;17:653–8.PubMedGoogle Scholar
  13. 13.
    Ichikawa W, et al. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer. 2004;91:1245–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Ichikawa W, et al. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer. 2006;119:1927–33.PubMedCrossRefGoogle Scholar
  15. 15.
    Napieralski R, et al. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res. 2005;11:3025–31.PubMedCrossRefGoogle Scholar
  16. 16.
    Koizumi W, et al. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Int J Cancer. 2010;126:162–70.PubMedCrossRefGoogle Scholar
  17. 17.
    Liu B, et al. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet. 2007;15:1049–53.PubMedCrossRefGoogle Scholar
  18. 18.
    Olaussen KA, et al. Bio Investigators: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.PubMedCrossRefGoogle Scholar
  19. 19.
    D’Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003;3:23–34.PubMedCrossRefGoogle Scholar
  20. 20.
    Goto S, et al. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res. 1999;31:549–58.PubMedCrossRefGoogle Scholar
  21. 21.
    Lee HS, et al. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer. 2001;92:1427–34.PubMedCrossRefGoogle Scholar
  22. 22.
    Choi IS, et al. Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer. Med Oncol. 2010; doi: 10.1007/s12032-009-9321-x.
  23. 23.
    Fujii R, Seshimo A, Kameoka S. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol. 2003;8:72–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Kodera Y, et al. Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil. Cancer Lett. 2007;252:307–13.PubMedCrossRefGoogle Scholar
  25. 25.
    Ichikawa W, et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer. 2003;89:1486–92.PubMedCrossRefGoogle Scholar
  26. 26.
    Shimizu T, Yamada Y, Yasui H, Shirao K, Fukuoka M. Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine. Anticancer Res. 2005;25:2997–3001.PubMedGoogle Scholar
  27. 27.
    Koizumi W, Saigenji K, Nakamaru N, Okayasu I, Kurihara M. Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor. Oncology. 1999;56:215–22.PubMedCrossRefGoogle Scholar
  28. 28.
    Shirota Y, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001;19:4298–304.PubMedGoogle Scholar
  29. 29.
    Kwon HC, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007;18:504–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • In Sil Choi
    • 3
  • Hye Seung Lee
    • 2
  • Keun-Wook Lee
    • 1
    Email author
  • Haeryoung Kim
    • 2
  • Ki Hwan Kim
    • 1
  • Yu Jung Kim
    • 1
  • Jee Hyun Kim
    • 1
  • Woo Ho Kim
    • 4
  • Jong Seok Lee
    • 1
  1. 1.Department of Internal MedicineSeoul National University Bundang Hospital, Seoul National University College of MedicineSeongnam-siKorea
  2. 2.Department of PathologySeoul National University Bundang Hospital, Seoul National University College of MedicineSeongnamKorea
  3. 3.Department of Internal MedicineSeoul Municipal Boramae Hospital, Seoul National University College of MedicineSeoulKorea
  4. 4.Department of PathologySeoul National University Hospital, Seoul National University College of MedicineSeoulKorea

Personalised recommendations